Table 2 Univariate and multivariate analysis of NST induced by blinatumomab

Age

3.09 (t-test)

0.0020

0.0035

1.01 (1.00—1.01)

Gender

0.87

0.3505

0.4915

0.95 (0.81–1.10)

Dermatological medications

31.54

 < .0001

0.5198

1.22 (0.67–2.21)

Systemic corticosteroids, excluding sexual hormones and insulin

25.38

 < .0001

0.8498

0.96 (0.63–1.47)

Systemic anti-infective agents

26.21

 < .0001

0.7018

0.94 (0.70–1.27)

Antineoplastic and immunomodulating agents

3.36

0.0669

0.1156

0.84 (0.68–1.04)

Musculoskeletal system medications

5.07

0.0243

0.0082

0.61 (0.43–0.88)

Sensory organ system medications

29.38

 < .0001

0.4777

0.81 (0.45–1.45)

Antiparasitic, insecticidal, and anthelmintic drugs

14.59

0.0001

0.1091

1.64 (0.90–3.00)

Digestive and metabolic system drugs

39.62

 < .0001

0.1009

1.44 (0.93–2.22)

Genitourinary system and sexual hormones

31.14

 < .0001

0.0276

1.37 (1.04–1.81)

Nervous system medication

58.39

 < .0001

 < .0001

1.94 (1.44–2.63)

Cardiovascular system medications

30.83

 < .0001

0.7011

1.09 (0.71–1.66)

Respiratory system medications

25.68

 < .0001

0.5712

0.88 (0.58–1.36)

Blood and hematopoietic organs medication

26.48

 < .0001

0.4292

1.17 (0.80–1.70)

Other miscellaneous drugs

21.03

 < .0001

0.5885

0.90 (0.60–1.34)